Eastern Money Choice data shows that as of April 13, 28 listed companies in the medical device category have disclosed their 2022 annual reports, of which 18 companies have achieved year-on-year growth in net profit, accounting for 64.29%.

Agena Bioscience and nRichDX said Friday that they have entered a commercial partnership to co-promote their products to researchers developing liquid biopsy applications on Agena's MassArray platform.

Merck and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

Alzheimer's disease (AD) is a common neurodegenerative disease that affects the cognitive and memory abilities of the brain.

Pillar Biosciences said on Thursday that it has acquired a nonexclusive license to high-throughput screening-related intellectual property from Dutch ag-bio firm KeyGene.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023.

Microorganisms are a group of tiny, invisible organisms that are mainly divided into fungi, actinomycetes, bacteria, spirochetes, rickettsiae, chlamydiae, mycoplasmas, and viruses. Different diseases correspond to different types of samples, including fluids obtained from patients' sputum, urine, blood, puncture fluid, cerebrospinal fluid, pus, and wound sites.

Naveris said Wednesday that Mayo Clinic began a Phase II trial of its circulating tumor DNA blood test, NavDx, to guide treatment for patients with HPV-driven head and neck cancer.

Agilent Technologies Inc. announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities.

On April 6, Sinocare released its annual report for 2022.

Avalon GloboCare and Qi Diagnostics on Tuesday announced their intention to co-develop a breathalyzer device for screening and the early detection of lung cancer.

Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to include companion diagnostic development for the pharma firm's investigational tyrosine kinase inhibitor repotrectinib.

Righton Gene announced on April 9 that in 2022, the company achieved operating revenue of CNY 424 million, up 45.83% year-on-year; attributable net profit of CNY 40,473,600, down 14.49% year-on-year; basic earnings per share of CNY 0.73.

Ultima Genomics and Genome Insight said on Monday that they are collaborating to develop affordable whole-genome sequencing testing for cancer patients.

The UK National Health Service said last week that it would offer genetic testing for Lynch syndrome to all patients diagnosed with bowel and endometrial cancer.